Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of LifeMD, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased LifeMD securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to LifeMD [2]. Group 2: Financial Results and Stock Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance from a previous range of $268 to $275 million down to $250 to $255 million [3]. - Following the announcement of the revised guidance, LifeMD's stock price dropped by 44.8% on August 6, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered over $438 million for investors in 2019 alone [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of a weight loss drug, which has resulted in a significant drop in its stock price following the termination of a partnership with Novo Nordisk [1][4][5]. Group 1: Company Overview - Hims & Hers Health is a telehealth company that offers prescription and over-the-counter medications, as well as personal care products [3]. Group 2: Legal Allegations - The class action lawsuit claims that during the class period from April 29, 2025, to June 23, 2025, Hims & Hers made false or misleading statements and failed to disclose material facts regarding its business practices [4]. - Specific allegations include the deceptive promotion and sale of illegitimate versions of Novo Nordisk's weight loss drug, Wegovy®, which posed risks to patient safety [4]. - The lawsuit also suggests that these actions led to a significant risk of termination of the collaboration with Novo Nordisk [4]. Group 3: Impact of the Lawsuit - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing the deceptive practices as the reason, which resulted in a more than 34% decline in Hims & Hers' stock price [5].

Summary of Conference Call Company Overview - The conference call involved HIMS, a healthcare technology company focused on improving consumer healthcare experiences through technology and personalized solutions [3][4][5]. Core Industry Insights - The healthcare industry is evolving with technology aimed at reducing friction in consumer experiences, similar to advancements seen in other sectors like transportation (Uber) and entertainment (Netflix) [4]. - HIMS aims to democratize healthcare services, making them accessible to a broader consumer base while enhancing capabilities such as lab diagnostics and personalized treatments [5][10]. Strategic Priorities - HIMS' strategy focuses on leveraging technology to enhance consumer healthcare experiences, emphasizing awareness, access, and affordability [3]. - The company has expanded its platform capabilities significantly, reducing the time for patients to connect with medical experts from weeks to often less than 24 hours [5]. Personalization and Investments - Recent acquisitions and capital expenditures are aimed at enhancing personalized healthcare solutions, driven by consumer feedback on treatment adherence and side effects [6][7]. - HIMS has over 2.4 million subscribers, providing a substantial data set to improve personalized healthcare offerings [8]. AI Integration - HIMS is utilizing AI to streamline provider experiences and enhance the customer journey, including diagnostic tools that optimize treatment plans based on consumer attributes [11][12]. - Future developments may include AI-driven nutritional coaching and mental health support [14]. Market Opportunities - HIMS plans to launch new offerings in low testosterone and menopausal support, identifying these markets as large and underserved [15][16]. - The company sees potential in addressing conditions that consumers may not be aware they have, thus expanding the market for treatments [16]. Weight Loss Segment - The weight loss segment remains a key focus, with over 100 million individuals in the U.S. facing weight-related challenges [21]. - HIMS emphasizes the importance of provider interaction and holistic treatment approaches beyond medication [23][24]. Regulatory Considerations - Concerns regarding regulatory risks associated with compounding medications were addressed, with HIMS asserting compliance with existing laws and transparency in consumer data [27][30]. International Expansion - HIMS is expanding into European markets, leveraging insights gained from its UK operations and the recent acquisition of Zava [35][36]. - The company plans to launch in Canada, anticipating the availability of generic semaglutide, which aligns with its strategy to address obesity challenges [40][41]. Financial Performance and Growth Drivers - Despite decelerating growth in core segments, HIMS reports strong performance in various specialties, with growth rates exceeding 55% in several areas [43][44]. - The company is focused on long-term strategies to enhance customer retention and expand its product offerings, particularly in sexual health [44][46]. Conclusion - HIMS is positioned to capitalize on significant market opportunities through technology-driven personalization, strategic acquisitions, and a focus on consumer needs in the evolving healthcare landscape [39][46].

Core Viewpoint - Hims & Hers Health CEO Andrew Dudum sold a significant block of shares, marking the largest insider transaction since the company went public, raising approximately $33.4 million from the sale of 660,000 shares at an average price of $50.58 [1][4][5] Insider Trading Details - The sale was conducted outside of Dudum's pre-established trading plan and was made through a family trust [3] - Despite the sale, Dudum remains the largest individual shareholder with about 8 million shares held indirectly through various trusts, valued at approximately $388 million [4][5] Purpose of Sale - The company stated that the sale was for "tax and philanthropic purposes" and that Dudum continues to hold his full personal stake, emphasizing his commitment to the company's long-term growth [5] Market Performance - Hims & Hers has seen its stock price double over the past year, although it experienced a decline of over 4% on the day of the report and more than 13% for the week [8][10] - The company reported adjusted earnings of $0.17 per share for Q2 2025, exceeding estimates, while revenue rose 73% year-over-year to $544.8 million, though it fell short of analyst projections [10][11] Future Projections - For the third quarter, Hims & Hers projects revenue between $570 million and $590 million, aligning with analyst expectations of $583 million [11]

Core Insights - Hims & Hers Health, Inc. operates at the intersection of digital health and consumer wellness, utilizing a vertically integrated telehealth platform for personalized, subscription-based care [1][2] - The company emphasizes accessibility, personalization, and scalability, leveraging data from millions of clinical interactions to refine its offerings and enhance patient engagement [2][3] - Hims & Hers plans to expand internationally into markets such as the U.K., Germany, and Canada, while focusing on AI-driven personalization to meet evolving patient expectations [3] Company Overview - Hims & Hers provides a wide range of health services, including sexual health, dermatology, and weight loss, supported by nearly 1,500 licensed providers [1][2] - The service model combines direct-to-consumer approaches with integrated provider consultations, pharmacy services, and app-based tools for tailored treatment plans [1][7] - Subscription revenue is a key component of Hims & Hers' business model, ensuring predictable income streams and fostering deeper patient retention [2] Financial Performance - Hims & Hers shares have increased by 106.7% year to date, significantly outperforming the industry growth of 17.8% [6] - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share indicates a 137% improvement from 2024 [8] - The company's forward 12-month price-to-sales ratio is 4.2X, lower than the industry average of 5.6X but higher than its three-year median of 2.3X [10] Earnings Estimates - The current quarter consensus estimate for earnings per share is $0.12, with projections of $0.14 for the next quarter and $0.64 for the current year [11] - Year-over-year growth estimates show a 100% increase for the current quarter and a 137.04% increase for the current year [11]

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations is from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements from the company could lead to the termination of its collaboration with Novo Nordisk [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment by August 25, 2025 [3]. - Registration allows shareholders to receive updates through a portfolio monitoring software regarding the case's status [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices [4]. - The firm is dedicated to ensuring companies adhere to responsible business practices and good corporate citizenship [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock [4].

Core Viewpoint - Hims & Hers Health is experiencing significant revenue growth and expanding its subscriber base, despite volatility in its stock price and challenges in the weight loss segment [1][4][6]. Financial Performance - In Q2, Hims & Hers reported a revenue increase of 73% year-over-year, reaching $544.8 million, which was at the high end of its forecast but below analyst expectations [4][10]. - Monthly online revenue per subscriber rose by 30% to $74, and the total number of subscribers increased by 31% to nearly 2.44 million [4][10]. - Adjusted EBITDA surged to $82.2 million, a 109% increase from the previous year, and adjusted EPS was $0.17, exceeding analyst expectations [8][10]. Subscriber Growth - The number of customers using at least one personalized subscription grew by 89% to 1.5 million, making up over 60% of the subscriber base [5]. - The company noted a 170% increase in subscribers using personalized treatment plans for multiple conditions, reaching over 500,000 [5]. Marketing and Expenses - Marketing expenses increased by 50% to nearly $218 million, accounting for 40% of revenue, down from 46% a year ago, indicating improved efficiency [7][10]. - The gross margin was reported at 76%, reflecting a decrease of 500 basis points year-over-year [10]. Future Outlook - Hims & Hers maintains its 2025 revenue forecast of $2.3 billion to $2.4 billion, representing growth of 56% to 63%, and adjusted EBITDA guidance of $295 million to $335 million [10][11]. - For Q3, the company projects revenue between $570 million and $590 million, with adjusted EBITDA of $60 million to $70 million [11]. - The company is planning international expansion, starting with Canada and targeting Europe, Latin America, and Asia in the coming years [11][12]. Growth Opportunities - Hims & Hers is expanding into new areas, including hormonal health, which is expected to contribute to its long-term revenue goals of $6.5 billion by 2030 [12]. - The company continues to see strong growth across various health categories, despite challenges in the weight loss segment [13]. Valuation - The stock trades at a forward P/E ratio of around 55 based on 2025 analyst estimates, with a PEG ratio under 0.6, indicating potential undervaluation [14]. - The price-to-sales multiple is 5.5 times 2025 estimates, suggesting reasonable pricing given the high gross margins of the subscription business [14].

Core Insights - Hims & Hers is experiencing rapid revenue growth but is currently facing a legal battle that poses risks to its future performance [1][4] - The company's stock has seen a significant decline of 17% this week and is down 25% from its all-time highs, despite a remarkable 400% increase over the past five years [1][2] Financial Performance - In Q2 2025, Hims & Hers reported a 73% year-over-year revenue growth, exceeding $500 million, driven by a 30% increase in total subscribers and a 30% rise in spending per active subscriber [2] - The company has achieved $2 billion in trailing revenue, marking an increase of over 1,000% in the last five years, solidifying its position as a leading telehealth provider [6] Legal Challenges - Hims & Hers is embroiled in a legal dispute with Novo Nordisk, stemming from allegations of selling knockoff weight loss drugs after a partnership ended due to disagreements [3][4] - The company is accused of illegally selling patented weight loss drugs at a discount now that the shortage has resolved, raising concerns among investors about the potential impact on future revenue and profitability [3][4] Market Position - Hims & Hers has made significant market share gains in the telehealth sector, particularly in the online provision of drugs and medical treatments [6] - Despite its strong growth trajectory, the ongoing legal issues may deter potential investors from buying the stock at its current dip [7][8]

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2]. - It is alleged that this situation created a substantial risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].